Last reviewed · How we verify
NCT07249411: Exosom2025-1
In Vitro Oocyte Maturation With Autologous Exosomes in Women
NA trial testing MI oocytes were cultured in conventional IVM medium supplemented with 10 µg of autologous exosomes obtained using the ExoSMarT® exosome filtration system in Diminished Ovarian Reserve in 32 participants. Completed in 31 January 2025.
31 January 2025
Quick facts
| Lead sponsor | Biotech Fertility C.A. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 2 January 2023 |
| Primary completion | 31 January 2025 |
| Estimated completion | 31 January 2025 |
| Sites | 1 location across Venezuela |
Drugs / interventions tested
- MI oocytes were cultured in conventional IVM medium supplemented with 10 µg of autologous exosomes obtained using the ExoSMarT® exosome filtration system
Conditions studied
- Diminished Ovarian Reserve — all drugs for Diminished Ovarian Reserve →
Sponsor
Biotech Fertility C.A.
Who can join
Adults 38 to 48, female only, with Diminished Ovarian Reserve. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a preliminary, prospective, randomized, controlled clinical trial designed to evaluate the safety and feasibility of supplementing in vitro maturation (IVM) media with autologous exosomes in women with diminished ovarian reserve undergoing assisted reproductive technology. The purpose of the study is to determine whether autologous exosomes can support the meiotic progression of immature metaphase I oocytes during a 24-36 hour culture period and to establish whether the intervention is safe, biologically feasible, and suitable for further clinical evaluation. Mature oocytes obtained after culture are fertilized using intracytoplasmic sperm injection, and resulting embryos are cryopreserved for future transfer in a subsequent phase of the research. No embryo transfer is performed during this preliminary phase.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07249411
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diminished Ovarian Reserve
Currently open trials in the same condition.
- NCT07535983 — Bushen Yiqi Formula Combined With Dehydroepiandrosterone in Women With Diminished Ovarian Reserve · Phase 1, PHASE2 · recruiting
- NCT06794047 — The Effect of VitC on IVF Outcome of DOR Patients · NA · recruiting
- NCT07124260 — Characterization of Gut and Tongue Coating Microbiota in Patients With Diminished Ovarian Reserve · recruiting
- NCT06395623 — Study of Acupoints in Diminished Ovarian Reserve Based on Biological Characteristics · recruiting
- NCT06096766 — The Correlation Between Ovarian Function and Serum Biomarkers · recruiting
Other Biotech Fertility C.A. trials
Trials by the same sponsor.
- NCT06773572 — Use of Autologous Exosomes vs Platelet Growth Factors to Regenerate the Ovary in Women With Infertility (Exosomas2024-1) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07249411 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Biotech Fertility C.A.
- Last refreshed: 25 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07249411.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing